Fig. 1From: Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trialKaplan-Meier estimates of disease-free survival for mITT patients (A), stage II patients (B), and stage III patients (C). HR, hazard ratio; PC, perioperative chemotherapy; AC, adjuvant chemotherapyBack to article page